Comprehensive Guide to Imipramine: Uses, Dosage, Side Effects, and More
What is Imipramine?
Overview of Imipramine
Generic Name: Imipramine
Brand Name: Tofranil, generics
Drug Group: Tricyclic antidepressant (TCA)
Commonly Used For
This medication is used to:
- Treat major depressive disorder (MDD).
- Manage nocturnal enuresis in children.
- Control chronic pain and neuropathic conditions.
Key Characteristics
Form: Oral tablets (10 mg, 25 mg, 50 mg), capsules, and injection (detailed in Dosage section).
Mechanism: Blocks serotonin and norepinephrine reuptake, with anticholinergic, antihistaminic, and alpha-adrenergic effects.
Approval: FDA-approved (1959 for Tofranil) and EMA-approved for depression and enuresis.
Indications and Uses of Imipramine
Imipramine is indicated for psychiatric, neurological, and urological conditions, leveraging its broad neurochemical effects:
Major Depressive Disorder (MDD): Treats moderate to severe depression in adults, improving mood, sleep, and energy levels, supported by long-term efficacy studies and meta-analyses.
Nocturnal Enuresis (Bedwetting): Manages bedwetting in children (6+ years), reducing nighttime accidents, often used short-term, per pediatric urology guidelines.
Chronic Pain Syndromes: Controls neuropathic pain (e.g., diabetic neuropathy, postherpetic neuralgia), fibromyalgia, and tension headaches, with evidence from pain management trials.
Panic Disorder: Used off-label to reduce frequency and severity of panic attacks, improving quality of life, supported by anxiety disorder research.
Generalized Anxiety Disorder (GAD): Employed off-label for persistent anxiety, with gradual onset of relief, under psychiatric supervision.
Attention-Deficit/Hyperactivity Disorder (ADHD): Investigated off-label in children with comorbid depression or enuresis, enhancing focus and emotional regulation, with pediatric psychiatry data.
Bulimia Nervosa: Explored off-label to reduce binge-purge cycles, though less effective than SSRIs, with eating disorder studies.
Migraine Prophylaxis: Used off-label to prevent chronic migraines, reducing frequency and intensity, supported by neurology research.
Irritable Bowel Syndrome (IBS): Managed off-label for IBS with predominant pain and diarrhea, improving gut-brain axis function, with gastroenterology evidence.
Post-Traumatic Stress Disorder (PTSD): Investigated off-label for PTSD with depressive features, reducing hyperarousal and nightmares, with trauma-focused studies.
Dosage of Imipramine
Dosage for Adults
Major Depressive Disorder:
- Initial: 25–50 mg/day at bedtime, increase by 25–50 mg every 3–7 days.
- Maintenance: 100–200 mg/day (max 300 mg/day in severe cases), divided or at bedtime.
Chronic Pain:
- Initial: 10–25 mg at bedtime, titrate to 50–150 mg/day based on pain relief.
Dosage for Children
Nocturnal Enuresis (6–17 years):
- 6–12 years: 25 mg 1 hour before bedtime; max 50 mg if <25 kg, 75 mg if >25 kg.
- 12 years: 25–75 mg at bedtime, under pediatric supervision.
- Not recommended under 6 years.
Depression (off-label, >12 years):
- Initial: 25 mg/day, titrate to 50–100 mg/day, max 200 mg/day.
Dosage for Pregnant Women
Pregnancy Category D: Avoid unless benefits outweigh risks (e.g., severe MDD). Use lowest effective dose with fetal monitoring; consult an obstetrician.
Dosage Adjustments
Renal Impairment: No adjustment needed; monitor in severe cases.
Hepatic Impairment: Reduce dose by 50% in moderate impairment; avoid in severe cases.
Elderly: Start with 10–25 mg/day; max 100 mg/day due to anticholinergic sensitivity.
Cardiac Disease: Start with 10 mg/day; monitor ECG for QT prolongation.
Additional Considerations
- Take this active ingredient with or after food to reduce stomach upset.
- Use a pill organizer for consistent bedtime dosing.
How to Use Imipramine
Administration:
- Swallow tablets/capsules whole with water, preferably at bedtime to reduce daytime sedation.
- Avoid crushing or chewing; use liquid form if swallowing is difficult.
Timing: Take once or twice daily, with the largest dose at bedtime.
Monitoring: Watch for dry mouth, constipation, dizziness, or mood changes.
Additional Tips:
- Store at 20–25°C (68–77°F), protecting from moisture and light.
- Keep out of reach of children due to overdose risk.
- Report suicidal thoughts, rapid heartbeat, or seizures immediately.
Contraindications for Imipramine
This drug is contraindicated in:
Hypersensitivity: Patients with a known allergy to Imipramine or TCAs.
Recent Myocardial Infarction: Contraindicated due to arrhythmia risk.
MAO Inhibitors: Avoid within 14 days of MAOIs (e.g., phenelzine) due to serotonin syndrome.
Narrow-Angle Glaucoma: Contraindicated due to anticholinergic effects.
Severe Urinary Retention: Avoid in prostate hyperplasia.
Warnings & Precautions for Imipramine
General Warnings
Suicidal Ideation: Increased risk in young adults; monitor mood closely.
Cardiac Arrhythmias: Risk of QT prolongation and torsades de pointes; perform baseline ECG.
Anticholinergic Effects: Dry mouth, constipation, blurred vision; use caution in elderly.
Serotonin Syndrome: Risk with SSRIs, SNRIs, or triptans; discontinue if agitation occurs.
Seizure Threshold: Lowers threshold; avoid in epilepsy unless controlled.
Additional Warnings
Orthostatic Hypotension: Risk of falls; rise slowly from sitting.
Hepatotoxicity: Rare liver injury; monitor LFTs in long-term use.
Bone Marrow Suppression: Rare agranulocytosis; monitor CBC if fever occurs.
Withdrawal Syndrome: Taper slowly to avoid flu-like symptoms.
Photosensitivity: Increased sunburn risk; use sunscreen.
Use in Specific Populations
Pregnancy: Category D; avoid unless critical; monitor neonate for withdrawal.
Breastfeeding: Excreted in breast milk; monitor infant for sedation.
Elderly: Higher risk of confusion, falls; start low, go slow.
Children: Limited to 6+ years for enuresis; monitor growth.
Renal/Hepatic Impairment: Adjust dose; avoid in severe cases.
Additional Precautions
- Inform your doctor about heart disease, glaucoma, or seizure history before starting this medication.
- Avoid abrupt cessation; taper over 2–4 weeks.
Overdose and Management of Imipramine
Overdose Symptoms
Overdose may cause:
- Drowsiness, confusion, or coma.
- Severe cases: Cardiac arrest, seizures, or respiratory depression.
- Dry mouth, dilated pupils, or tachycardia as early signs.
- Hyperthermia with extremely high doses.
Immediate Actions
Contact the Medical Team: Seek immediate medical help.
Supportive Care: Administer activated charcoal, IV fluids, and benzodiazepines for seizures.
Specific Treatment: Use sodium bicarbonate for QRS widening; avoid physostigmine.
Monitor: Check ECG, vital signs, and mental status for 24–72 hours.
Additional Notes
- Overdose is life-threatening; store securely.
- Report persistent symptoms (e.g., irregular heartbeat, hallucinations) promptly.
Side Effects of Imipramine
Common Side Effects
- Dry Mouth (40–60%, use sugar-free gum)
- Constipation (20–40%, increase fiber)
- Drowsiness (15–35%, take at bedtime)
- Weight Gain (10–25%, monitor diet)
- Dizziness (10–20%, rise slowly)
These effects may subside with dose adjustment.
Serious Side Effects
Seek immediate medical attention for:
- Cardiac: Arrhythmias, palpitations, or syncope.
- Neurological: Seizures, confusion, or serotonin syndrome.
- Psychiatric: Suicidal thoughts or mania.
- Hematologic: Agranulocytosis or thrombocytopenia.
- Allergic: Rash, angioedema, or anaphylaxis.
Additional Notes
- Regular monitoring for ECG, weight, and mood is advised.
- Report any unusual symptoms (e.g., fever with sore throat, severe headache) immediately.
Drug Interactions with Imipramine
This active ingredient may interact with:
- MAO Inhibitors: Risk of serotonin syndrome; 14-day washout required.
- SSRIs/SNRIs: Increases TCA levels; monitor for toxicity.
- Anticholinergics: Enhances side effects (e.g., atropine); avoid.
- CYP2D6 Inhibitors: Increases levels (e.g., fluoxetine); reduce dose.
- Alcohol/CNS Depressants: Potentiates sedation; avoid.
Action: Provide your healthcare provider with a complete list of medications.
Patient Education or Lifestyle
Medication Adherence: Take this tricyclic antidepressant as prescribed, even if mood improves.
Monitoring: Report suicidal thoughts, rapid heartbeat, or dry mouth immediately.
Lifestyle: Avoid alcohol; limit caffeine to reduce anxiety.
Diet: Take with food; increase fiber for constipation.
Emergency Awareness: Know signs of overdose or serotonin syndrome; seek care if present.
Follow-Up: Schedule check-ups every 1–3 months to monitor ECG, weight, and therapeutic response.
Pharmacokinetics of Imipramine
Absorption: Well-absorbed orally (peak at 1–2 hours); food delays but does not reduce absorption.
Distribution: Volume of distribution ~15 L/kg; 96% protein-bound.
Metabolism: Hepatic via CYP2D6 to desipramine (active); extensive first-pass.
Excretion: Primarily renal (70%) as metabolites; half-life 11–25 hours.
Half-Life: 11–25 hours, longer in poor CYP2D6 metabolizers.
Pharmacodynamics of Imipramine
This drug exerts its effects by:
Blocking serotonin and norepinephrine reuptake, enhancing mood.
Antagonizing muscarinic, histaminic, and alpha-1 receptors, causing side effects.
Downregulating beta-adrenergic receptors with chronic use, contributing to antidepressant action.
Exhibiting dose-dependent cardiac and anticholinergic toxicity.
Storage
Temperature: Store at 20–25°C (68–77°F); protect from moisture.
Protection: Keep in original container, away from light.
Safety: Store in a locked container out of reach of children due to overdose risk.
Disposal: Dispose of unused tablets per local regulations or consult a pharmacist.
Frequently Asked Questions (FAQs)
Q: What does Imipramine treat?
A: This medication treats depression and bedwetting.
Q: Can this active ingredient cause weight gain?
A: Yes, weight gain may occur; monitor diet.
Q: Is Imipramine safe for children?
A: Yes, for 6+ years for enuresis with a doctor’s guidance.
Q: How is this drug taken?
A: Orally, usually at bedtime, as directed.
Q: How long is Imipramine treatment?
A: 6–12 months for depression; short-term for enuresis.
Q: Can I use Imipramine if pregnant?
A: No, avoid unless critical; consult a doctor.
Regulatory Information
This medication is approved by:
U.S. Food and Drug Administration (FDA): Approved in 1959 (Tofranil) for depression and enuresis.
European Medicines Agency (EMA): Approved for MDD and nocturnal enuresis.
Other Agencies: Approved globally; consult local guidelines.
References
- U.S. Food and Drug Administration (FDA). (2023). Tofranil (Imipramine) Prescribing Information.
- Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
- European Medicines Agency (EMA). (2023). Imipramine Summary of Product Characteristics.
- EMA’s comprehensive information on the medication’s indications and precautions in Europe.
- National Institutes of Health (NIH). (2023). Imipramine: MedlinePlus Drug Information.
- NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
- World Health Organization (WHO). (2023). WHO Model List of Essential Medicines: Imipramine.
- WHO’s inclusion of Imipramine for mental health.
- Journal of Clinical Psychiatry. (2022). Imipramine in Chronic Pain.
- Peer-reviewed article on Imipramine efficacy (note: access may require a subscription).
